Chemistry:Mecasermin

From HandWiki
Short description: Pharmaceutical drug
Mecasermin
Clinical data
Trade namesIncrelex
Other namesFK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life5.8 hours[2]
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC331H512N94O101S7
Molar mass7648.71 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[2][3][4]

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[2]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[5] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[5]

References

External links